Why Retatrutide Raises Your Heart Rate Without Raising Your Metabolism
*Community-sourced analysis of the energy expenditure myths around retatrutide, compiled from the r/retatrutide discourse corpus. Retatrutide is an investigational drug, this article is for research use only, and nothing in it is medical advice.*
*Community-sourced analysis of the energy expenditure myths around retatrutide, compiled from the r/retatrutide discourse corpus. Retatrutide is an investigational drug, this article is for research use only, and nothing in it is medical advice.*
I · The heart rate bump is a class effect
The six-beat resting pulse increase is a class effect that tracks the drug’s potency, and it says nothing about a faster metabolism.
The most reported retatrutide side effect in the community is the heart rate bump, which shows up in the first weeks and produces a steady stream of worried posts from people who just checked their resting pulse on a smartwatch. The trial numbers the community quotes are consistent across the whole corpus: an average increase of about 6 beats per minute at the 12mg dose at the end of the 48-week phase 2 trial, against about 3 beats per minute for tirzepatide at 72 weeks, and the educator’s read of the phase 2 data is that the bump was already on its way down by the end of the trial, since he describes it as “6bpm and declining at the end of the phase 2 trials”. 1 2
The comparison between the two drugs matters because it places the number in the right category, since tirzepatide, semaglutide, and retatrutide all raise resting heart rate to some degree, and the size of the bump tracks the potency of the drug rather than any special property of retatrutide’s glucagon arm. 2 The community’s one-liner for the difference is stripped to the essentials: “Tirz increases it about 3 bpm.” and “Reta increases it about 6 bpm.” 1 The strongest evidence that the bump is a class phenomenon comes from the most surprising corner of the record, because the GLP-1 drug with the largest heart rate increase in its trials is orforglipron, which engages only the GLP-1 receptor, and the educator’s framing is that “The GLP-1 with the largest increase in heart rate is actually orforglipron, weirdly enough, and it only targets GLP-1”. 3 If the bump were a glucagon effect, the GLP-1-only drug would sit at the back of the pack, and it leads it instead.
The phase 1 record adds the second piece of the pattern, since the outsized responses showed up in the healthiest volunteers, and the educator traces the data to the phase 1 program reported by Coskun and colleagues in 2022, where a single 4.5mg dose in a group with an average BMI of 23.2 and a resting pulse of 56.3 pushed the pulse to 88.5 by day 7, a jump of roughly 30 beats per minute, while even a 300mcg microdose moved the pulse by about 13 beats. 4 5 The community’s reading of that gradient is that people with the most cardiovascular headroom get the biggest bump, which is why the corpus treats a modest rise in an obesity patient as expected pharmacology and a large rise in a lean athlete as a fit question. The dismissive tone the educator uses for the panic is part of the corpus’s signature: “Your resting heart rate went up from 58 to 61? Congratulations, a doctor can no longer diagnose you with sinus bradycardia.” 6 A second sarcastic line makes the same point with the class comparison, which is why he can joke that “That extra 3 bpm is very very very scary.” 7
A resting heart rate between 60 and 100 beats per minute is unremarkable, and the community’s teaching case is a user at 76 beats per minute, which the educator describes in the corpus as a completely normal resting heart rate. A six-beat shift moves the number inside a range that clinicians read as normal.
The serious version of the same teaching is that heart rate increases are a class effect across a drug family whose outcome trials reduce major adverse cardiovascular events, which is an odd profile for a side effect that people treat as a cardiac emergency, and the practical read for anyone who watches their pulse is to expect the increase, follow the trend across weeks rather than any single reading, and treat a modest rise as the expected pharmacology of the class. 2
II · What six beats per minute cost your calorie budget
The heart spends about 100 to 150 calories a day in total, so the extra beats buy you calories you could count on your fingers.
The reason people reach for the metabolism explanation is that a faster heart rate reads like the body doing more work, and the wearable devices most users trust actively reinforce that reading by converting heart rate into calories burned. The community’s arithmetic on what the heart actually costs cuts the story down to size, and the educator’s phrasing has become the standard answer in the subreddit: “Your heart uses 100-150 calories over the course of a 24-hour day… You might burn enough extra calories to count them on your fingers.” 8
Your heart uses 100-150 calories over the course of a 24-hour day… You might burn enough extra calories to count them on your fingers.
Community report, r/retatrutide discourse, 2026
The same line of arithmetic shows up in the packet record with the heart’s share of resting metabolic rate at roughly 110 kcal a day, and the more interesting number is the rate-pressure product, a measure of cardiac work that multiplies heart rate by systolic blood pressure, which decreased from 8840 to 8655 at the 12mg dose in the phase 2 trial because blood pressure fell enough to offset the faster pulse. 9 The community reads that as the heart working no harder overall, which is why the educator states the teaching flatly: “You’re not actually burning more calories. Reta caused your heart rate to run higher than it normally would.” 10
The tracker problem follows directly from the heart math, because a device that prices every extra beat as calories will credit a retatrutide user with a burn the biology does not support, and the community’s position is that fitness apps miscalculate on exactly this point. 10 A six-beat increase against a resting pulse of 70 is a handful of extra beats per minute across the day, and even if the heart burned slightly more at the higher rate, the slice of the daily budget that moves is tiny enough to be invisible on the scale, which is the whole point of the fingers-counting line.
The error compounds because wearables apply heart-rate-based calorie formulas designed for exercise to a resting state, so a user whose pulse runs six beats higher all day gets an inflated active-calorie line. The community’s rule is to treat the tracker’s calorie readout as entertainment and its heart rate trend as the useful signal.
The takeaway is that the heart rate bump is a side effect with a negligible energy price, and the honest response to a wearable that claims extra calories is to ignore the estimate and watch the pulse trend instead. 9
III · The 15% energy expenditure claim stays unresolved
The claim that retatrutide raises energy expenditure by 15% circulates widely, and the honest position is that it remains unresolved.
The metabolism narrative does not stop at heart rate, because a second claim travels through the same content ecosystem with a specific number attached: retatrutide increases total energy expenditure by roughly 15%, enough to matter on its own. The number has a real ancestry, since short-term glucagon infusion studies in humans have reported energy expenditure increases in the range of 150 to 200 kcal a day, which works out to roughly 14 to 15% of daily expenditure, but the same literature contains negative trials, holds no long-term human data, and carries a real risk that any acute effect fades with continued exposure. 11 The community’s summary of the same evidence is deliberately hedged, with the educator describing reta as something that “might increase energy consumption a little bit but not drastically”, with a ballpark of about 125 kcal a day at the optimistic end, and the line he repeats most often is that “the appetite suppression is doing a lot more work than that”. 12
The honest position, repeated across multiple packets, is that the human expenditure question has no answer yet, and the educator’s most quoted statement on the topic is worth reading in full: “We don’t actually even know if it increases metabolism at all. That’s still hypothetical and undemonstrated.” 13
We don’t actually even know if it increases metabolism at all. That’s still hypothetical and undemonstrated.
Community report, r/retatrutide discourse, 2026
The 15% figure circulates in influencer summaries of the glucagon infusion literature, and the flagged conflict in the claims record is exactly this gap: the retatrutide-specific version of the claim has not been demonstrated in any human trial, so the responsible treatment of the number is unresolved uncertainty, and the claim stays out of the fact column until a metabolic-chamber study puts it there. 11 The mechanism that could produce such an effect is where the speculation lives, and the educator’s preferred candidate is a futile cycle, a process where energy is spent on work that cancels itself out, since he says that “If reta does increase energy expenditure in a meaningful way it’s most likely doing so via some form of futile cycle.” 14 The candidate mechanisms he names include futile lipid cycling and the biology reviewed in a Nature Metabolism paper he links, and he keeps the whole question inside a hedge. 12 The older human glucagon studies are inconsistent with each other as well, which is what a field looks like when the acute infusion data and the chronic treatment data have not been reconciled. 15
A metabolic-chamber trial that measures human energy expenditure directly is the standard that would settle it, and the educator reports that the retatrutide version of such a trial has finished collecting data, with his phrasing that “the trial is actually finished but it might be awhile before results are written and published”. 15
The takeaway is that a 15% metabolism boost is a claim with a plausible ancestry and no human proof, and anyone who reads it in marketing copy should hold it as a hypothesis the field has not yet tested in people. 11
IV · The mouse boost that runs on low amino acids
The only demonstrated energy expenditure boost sits in mice, and even there it depends on obesity and low amino acid levels.
The expenditure question changes character when the subject becomes a rodent, because the mouse data do show a real effect, and the community’s handling of that gap is one of its best habits: state the mouse finding, then state plainly that human translation is unknown. The educator’s formulation is unambiguous, since he says that “there’s not actually any evidence that reta increases energy expenditure in humans. The only evidence for that happening is in mice”, and he applies the same standard to tirzepatide, which “increases energy expenditure in mice but not in humans”. 16
The mouse effect has conditions attached. The boost appears in obese mice and stays absent in lean mice, which the corpus summarizes with the line that “It only works in fat mice… It continues to work even after the fat mice lose their excess weight”, while the lean animals cannot initiate the effect but can maintain it once it starts. 17 The second condition is about protein, and it is the one the community treats as a genuine tradeoff, since a mouse study found that the expenditure increase depended on low amino acid levels, and raising protein intake to protect lean mass blocked the effect: “There was a mouse study that found that the increase in energy expenditure was contingent upon low amino acid levels and that increasing protein intake to prevent lean mass catabolism also blocked the energy expenditure effect.” 18
The tradeoff explains the educator’s priority order, because he reports that he will not sacrifice muscle to chase an expenditure boost that is unproven in humans, and his protein recommendations throughout the corpus run high for exactly that reason. 18 The same packet notes that the brown-adipose thermogenesis story that sometimes appears in marketing is mouse-only as well, with glucagon holding the older human expenditure studies and the GIP arm contributing nothing demonstrated in people. 14 The conditions are exactly the ones a weight loss user would refuse to accept, since the boost wants an obese, low-protein mouse, while the human on retatrutide is usually losing weight on a deliberate protein intake and getting leaner.
The community’s reading is that chasing the mouse expenditure effect means running low amino acids, which is the opposite of the muscle-protection strategy most users actually want. The practical choice is to eat the protein and let the unproven expenditure effect go, since the appetite mechanism keeps working regardless.
The takeaway is that the rodent data describe a conditional, low-protein phenomenon with an unknown human translation, and the sensible use of that information is to treat high protein as the safer bet than an unproven metabolic boost. 17
V · The appetite signal does the work
The deficit that produces the weight loss is intake-driven, and the appetite signal carries the load.
Strip the metabolism story away and the mechanism that remains is the appetite signal, which is where the community’s confidence is highest and the trial record is most consistent. The educator’s summary of the mechanism is about as direct as it gets: “Reducing your appetite is the vast majority of how that works, maybe even all of it.” 19 The energy-balance framing behind that claim is worth walking through, because it is where the expenditure question dies a quiet death, since the weight loss observed in the phase 2 program that Jastreboff and colleagues published in the New England Journal of Medicine, an average of 24.2% at 48 weeks at the top dose, requires a sustained daily deficit in the neighborhood of 600 kcal, and the question is where that deficit comes from. 20 21
The community’s arithmetic compares the deficit requirement across drugs: reta needs roughly 600 kcal a day against roughly 365 for semaglutide, a gap of about 235 kcal a day that an expenditure effect would have to fill, and the educator’s read of the gap is skeptical, since he says that “235 calories/day is probably unrealistically high and 0 is a distinct possibility supported by several studies”. 19 The growth hormone analogy makes the same point from the other direction, with the corpus stating the principle as “things like growth hormone which measurably increase expenditure don’t typically cause weight loss”. 22 If a real expenditure boost were the lever, growth hormone would be a weight loss drug, and it is not, which is the cleanest argument available that expenditure is downstream of appetite in this story.
The metabolic-ward evidence points the same way, since the tirzepatide metabolic-adaptation study led by Ravussin’s group and published in Cell Metabolism in 2025 failed to calorie-match its participants, with the striking detail that “At week 18, none of the participants receiving tirzepatide were within the target range of 8% to 12% weight loss”, meaning the drug produced more loss than the energy-balance model predicted, which is the signature of an intake effect doing the work while the expenditure line stays flat. 23 The community reads that as the appetite signal winning, and Kevin Hall’s energy-balance work is the theoretical backing the educator reaches for when the plateau conversation comes up, since he says that “If you look at the work that guys like Kevin Hall have done on this it seems like it’s almost entirely due to people eating more”. 24
If you look at the work that guys like Kevin Hall have done on this it seems like it’s almost entirely due to people eating more.
Community report on Kevin Hall’s energy-balance research, r/retatrutide discourse, 2026
The ledger is the whole argument, because a 600 kcal daily deficit sustained over 48 weeks produces roughly the weight loss the phase 2 trial measured, and the only unknown is whether expenditure contributes anything at all. That is why the community treats the appetite signal as the mechanism and the expenditure question as a rounding error.
The takeaway is that the appetite signal is load-bearing, the deficit is real, and the expenditure story, if it exists at all, contributes a slice small enough to ignore for planning purposes. 19
VI · What your tracker gets wrong about the burn
Wearables convert heart rate into calories, and on retatrutide that conversion reads as fiction.
The practical damage of the metabolism myth happens on the wrist, because the same heart rate bump that produces Reddit panic produces an inflated calorie readout on any device that prices heart rate into burn. The community’s position is that fitness apps miscalculate here, and the mechanism of the error is simple: the apps were built to estimate the cost of exercise, where heart rate correlates with work, and they apply the same formula to a resting state running six beats higher for pharmacological reasons. 10
The tracker error is compounded by the metabolic adaptation that comes with weight loss itself, since energy-balance modeling in the literature shows increased intake dominating the picture after loss, and the community’s plateau teaching leans on the same modeling. 25 A wearable that cannot see intake will blame the plateau on a dead metabolism, which feeds the exact myth this article is dismantling. 25 The scale has its own blind spots in the first weeks, since early losses overstate fat loss, and the educator’s own experience is the canonical example: “I lost over 14 lbs my first week on reta. That wasn’t 14 pounds of fat.” 26
The one heart rate warning the community treats as real is the outsized response, since lean athletic users and PED users can see 20 to 40 beat increases, which the educator reads as “a strong clue that reta might not be a good fit for you”, and the phase 1 data show the same pattern. 4 27 The sarcasm that surrounds the normal case keeps the distinction sharp, since the community mocks the panic with lines like “your heart rate is gonna go up 6 bpm and you’ll probably die”, while treating a 30-plus beat response as a genuine fit signal. 27 The management advice for the outsized case is hydration and electrolytes first, and the community’s caution on beta blockers is that they only partially blunt the bump, since the glucagon-mediated portion bypasses them. 28
The community’s monitoring doctrine is to use the wearable for heart rate trends and sleep, to ignore its calorie estimates entirely, and to read the scale as a trend across weeks rather than a daily verdict, since water weight moves the number far more than fat does in any given week. The useful data are the pulse trend and the weight trend, which is where the appetite-driven loss actually shows up.
The takeaway is that the tracker’s calorie line is the least trustworthy number on the device while the drug is running, and the honest use of the hardware is pulse trends for the side effect and weight trends for the deficit, with the calorie estimate filed under fiction. 26
VII · The honest accounting
The metabolism story resolves to a class-effect heart rate, a small unresolved expenditure question, and an appetite signal that does the work.
Put the sections together and the accounting is straightforward. The heart rate bump is a class effect that tracks potency and costs a negligible number of calories, the 15% expenditure claim has an ancestry in short-term glucagon infusion studies but no human demonstration for retatrutide itself, the mouse data are conditional on obesity and low amino acids with unknown translation, and the deficit that produces the observed weight loss is carried by the appetite signal. 11 19 The open questions are real and worth naming, starting with the human metabolic-chamber trial that has finished collecting data with results pending, and extending to the possibility that any expenditure effect fades with continued exposure, which the infusion literature cannot test, plus the protein interaction that blocks the mouse boost and has no human counterpart studied. 15 11
The practical value of the honest accounting is that it changes expectations in a useful direction, because a person who understands that the drug works through appetite knows that the effort belongs in the kitchen, that protein intake is worth protecting, and that a wearable reporting extra calories is lying to them. 24 The community’s confidence in the appetite mechanism is the one thing the packets agree on, and the expenditure question, whatever the pending trial shows, sits downstream of a deficit that the appetite signal creates. 19
A human metabolic-chamber result would answer the narrow question of whether retatrutide raises resting or total expenditure in people, and it would also test whether any effect survives months of treatment, which is the tachyphylaxis question the infusion literature cannot answer. Until that result is published, the expenditure column stays blank.
Nothing in this article is medical advice. The quotes come from the r/retatrutide discourse corpus, a community of people reporting their own single-case outcomes, led by one knowledgeable amateur whose numbers are remarkably consistent but whose reports remain anecdotes, and the article is published for research use only. 29
- Community voice corpus, packet ret_8 §6: “Tirz increases it about 3 bpm.” and “Reta increases it about 6 bpm.”, roughly consistent with published data (tirz ~2-3, reta ~5-6 bpm).
- Community voice corpus, packet ret_4 §4: “It was 6bpm and declining at the end of the phase 2 trials.”, peaking near +10 bpm at months 4-5, and heart rate increases as a class effect across a MACE-reducing drug family. Anecdotal framing.
- Community voice corpus, packet ret_6 §4: orforglipron as the biggest heart rate offender among GLP-1 drugs despite engaging only the GLP-1 receptor. Anecdotal framing.
- Community voice corpus, packets ret_1 §4 and ret_8 §1: phase 1 single-dose data, 4.5mg in healthy volunteers (BMI 23.2, pulse 56.3) reaching 88.5 on day 7 (+30 bpm), and 300mcg reaching +13 bpm, anchored to the 2022 phase 1 program reported by Coskun and colleagues.
- Retatrutide phase 1 trial, Coskun et al., 2022, as cited in the corpus knowledge posture (packet ret_8 §1).
- Community voice corpus, packet ret_1 §7: the sinus-bradycardia line, byte-exact. Anecdotal.
- Community voice corpus, packet ret_8 §7: “That extra 3 bpm is very very very scary.”, sarcasm. Anecdotal.
- Community voice corpus, packet ret_6 §4: heart daily budget of 100-150 kcal over 24 hours and the count-them-on-your-fingers line. Anecdotal.
- Community voice corpus, packet ret_1 §6: heart share of resting metabolic rate ~110 kcal/day and rate-pressure product decreasing from 8840 to 8655 at 12mg in phase 2.
- Community voice corpus, packet ret_6 §4: “You’re not actually burning more calories. Reta caused your heart rate to run higher than it normally would.” and the fitness-app miscalculation teaching. Anecdotal.
- Community voice corpus, packet ret_2 §6: glucagon infusion studies ~150-200 kcal/day and +14-15% energy expenditure, with negative trials, no long-term human data, and tachyphylaxis risk. The reta-specific 15% claim is a flagged conflict (knowledge-foundry claim card retatrutide-energy-expenditure-15) treated here as unresolved.
- Community voice corpus, packet ret_1 §6: “might increase energy consumption a little bit but not drastically”, ~125 kcal/day ballpark, “the appetite suppression is doing a lot more work than that”, with futile lipid cycling and Nature Metabolism paper s42255-024-01003-0 as candidate mechanisms. Anecdotal framing.
- Community voice corpus, packet ret_4 §6: “We don’t actually even know if it increases metabolism at all. That’s still hypothetical and undemonstrated.” Anecdotal.
- Community voice corpus, packet ret_6 §6: “If reta does increase energy expenditure in a meaningful way it’s most likely doing so via some form of futile cycle.”; brown-adipose thermogenesis is mouse-only, and glucagon holds the older human expenditure studies. Anecdotal.
- Community voice corpus, packet ret_8 §6: “the trial is actually finished but it might be awhile before results are written and published”, plus the inconsistent older human glucagon studies. Anecdotal.
- Community voice corpus, packet ret_8 §6: “there’s not actually any evidence that reta increases energy expenditure in humans. The only evidence for that happening is in mice”, and “tirzepatide increases energy expenditure in mice but not in humans”. Anecdotal.
- Community voice corpus, packet ret_4 §6: “It only works in fat mice… It continues to work even after the fat mice lose their excess weight”; lean mice cannot initiate the effect but can maintain it. Anecdotal.
- Community voice corpus, packet ret_6 §6: the hypoaminoacidemia mouse study and the educator’s muscle-first priority order. Anecdotal.
- Community voice corpus, packet ret_4 §6: “Reducing your appetite is the vast majority of how that works, maybe even all of it.”; reta ~600 vs sema ~365 kcal/day deficit requirement; “235 calories/day is probably unrealistically high and 0 is a distinct possibility supported by several studies”. Anecdotal.
- Retatrutide phase 2 obesity trial, Jastreboff et al., New England Journal of Medicine, 2023 (as cited in the corpus, packet ret_1 §6): 24.2% mean weight loss at 48 weeks at the top dose.
- Community voice corpus, packet ret_4 §6: the energy-balance argument that the ~600 kcal/day deficit requirement must be filled by intake reduction, since an expenditure effect would be counteracted by compensatory eating. Anecdotal framing.
- Community voice corpus, packet cluster_research_biohacking §6: “things like growth hormone which measurably increase expenditure don’t typically cause weight loss”. Anecdotal.
- Ravussin tirzepatide metabolic-adaptation study, Cell Metabolism, 2025, as relayed in the corpus (packet ret_6 §6): the failure to calorie-match and “At week 18, none of the participants receiving tirzepatide were within the target range of 8% to 12% weight loss”.
- Community voice corpus, packet ret_4 §6: “If you look at the work that guys like Kevin Hall have done on this it seems like it’s almost entirely due to people eating more”. Anecdotal.
- Community voice corpus, packet ret_2 §6: energy-balance modeling showing increased intake dominates TDEE reduction (PMC11132924).
- Community voice corpus, packet ret_6 §4: “I lost over 14 lbs my first week on reta. That wasn’t 14 pounds of fat.” Anecdotal.
- Community voice corpus, packet ret_4 §4: 20-40 bpm increases in lean/PED users as “a strong clue that reta might not be a good fit for you”, and the sarcasm line “your heart rate is gonna go up 6 bpm and you’ll probably die”. Anecdotal.
- Community voice corpus, packets ret_2 §4 and ret_8 §4: hydration and electrolytes first, and beta blockers only partially blunt the bump because the glucagon-mediated portion bypasses them. Anecdotal.
- Corpus provenance: all community quotes are single-case anecdotes from r/retatrutide discourse (2025-2026) and stay labeled anecdotal; the account is a knowledgeable amateur with no clinician credentials, and the article is energy-expenditure education without clinical advice.